836 related articles for article (PubMed ID: 17335684)
1. The emerging role of novel therapies for the treatment of relapsed myeloma.
Richardson PG; Hideshima T; Mitsiades C; Anderson KC
J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
[TBL] [Abstract][Full Text] [Related]
2. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and the current trends in multiple myeloma therapy.
Dmoszyńska A
Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817
[TBL] [Abstract][Full Text] [Related]
4. Clinical update: novel targets in multiple myeloma.
Anderson KC
Semin Oncol; 2004 Dec; 31(6 Suppl 16):27-32; discussion 33. PubMed ID: 15799242
[TBL] [Abstract][Full Text] [Related]
5. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Lacy MQ; Tefferi A
Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
[TBL] [Abstract][Full Text] [Related]
6. Multiple myeloma: novel approaches for relapsed disease.
Lonial S
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 1():S18-23. PubMed ID: 18282362
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
Barlogie B
Semin Hematol; 2003 Oct; 40(4 Suppl 4):33-8. PubMed ID: 15015894
[TBL] [Abstract][Full Text] [Related]
8. New therapies in multiple myeloma.
Merchionne F; Perosa F; Dammacco F
Clin Exp Med; 2007 Sep; 7(3):83-97. PubMed ID: 17972050
[TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsed and refractory myeloma.
Kaufman J; Gleason C; Lonial S
Curr Hematol Malig Rep; 2009 Apr; 4(2):99-107. PubMed ID: 20425421
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
11. Evolving role of novel agents for maintenance therapy in myeloma.
Magarotto V; Palumbo A
Cancer J; 2009; 15(6):494-501. PubMed ID: 20010169
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
Lonial S; Richardson PG; San Miguel J; Sonneveld P; Schuster MW; Bladé J; Cavenagh J; Rajkumar SV; Jakubowiak AJ; Esseltine DL; Anderson KC; Harousseau JL
Br J Haematol; 2008 Oct; 143(2):222-9. PubMed ID: 18713253
[TBL] [Abstract][Full Text] [Related]
13. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
14. [New treatment of multiple myeloma].
Hulin C
Rev Med Interne; 2007 Oct; 28(10):682-8. PubMed ID: 17559982
[TBL] [Abstract][Full Text] [Related]
15. Management of double-refractory multiple myeloma.
Meadows JP; Mark TM
Curr Hematol Malig Rep; 2013 Dec; 8(4):253-60. PubMed ID: 23975677
[TBL] [Abstract][Full Text] [Related]
16. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Roziaková L; Mistrík M; Bátorová A
Klin Onkol; 2014; 27(5):318-25. PubMed ID: 25312708
[TBL] [Abstract][Full Text] [Related]
17. Multiple myeloma: improved outcomes with new therapeutic approaches.
Eshaghian S; Berenson JR
Curr Opin Support Palliat Care; 2012 Sep; 6(3):330-6. PubMed ID: 22871979
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
Chanan-Khan AA; San Miguel JF; Jagannath S; Ludwig H; Dimopoulos MA
Clin Cancer Res; 2012 Apr; 18(8):2145-63. PubMed ID: 22328563
[TBL] [Abstract][Full Text] [Related]
19. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Zangari M; Fink L; Zhan F; Tricot G
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
[TBL] [Abstract][Full Text] [Related]
20. The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
Laubach JP; Mahindra A; Mitsiades CS; Schlossman RL; Munshi NC; Ghobrial IM; Carreau N; Hideshima T; Anderson KC; Richardson PG
Leukemia; 2009 Dec; 23(12):2222-32. PubMed ID: 19741729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
